Neovascular prostate specific membrane antigen (PSMA) expression in bone and soft tissue sarcoma: a systematic analysis
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00179906%3A_____%2F25%3A10498105" target="_blank" >RIV/00179906:_____/25:10498105 - isvavai.cz</a>
Alternative codes found
RIV/61383082:_____/25:00001512 RIV/00216208:11150/25:10498105
Result on the web
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=D9Lu..sb4" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=D9Lu..sb4</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1007/s00428-025-04086-6" target="_blank" >10.1007/s00428-025-04086-6</a>
Alternative languages
Result language
angličtina
Original language name
Neovascular prostate specific membrane antigen (PSMA) expression in bone and soft tissue sarcoma: a systematic analysis
Original language description
Bone and soft tissue sarcomas are a highly heterogeneous group of rare cancers of mesenchymal origin. Treatment options other than surgery have limited efficacy due to low response rates with some exceptions. Radioligand therapy targeting prostate-specific membrane antigen (PSMA) may provide a novel treatment option, as it was recently suggested that soft tissue sarcomas express PSMA in the neovasculature, and on PET/CT imaging, multiple sarcomas have shown intense PSMA-tracer accumulation. Moreover, in prostate cancer patients, incidental PSMA uptake was seen in hemangiomas. In addition to confirming previous results in soft tissue sarcoma, the current study aims to systematically explore the expression of PSMA in bone tumors and in vascular tumors. Immunohistochemistry for PSMA was performed on a total of 706 tumors. High PSMA expression in the neovasculature was seen in 29% of the soft tissue sarcomas and 33% of the bone sarcomas. Malignant tumors showed a higher frequency of PSMA expression (score 2) as compared to benign tumors, with a high frequency in rhabdomyosarcoma (2 of 2, 100%), mesenchymal chondrosarcoma (14 of 20, 70%), undifferentiated sarcoma of bone (4 of 6, 67%) and of soft tissue (13 of 20, 65%), and osteosarcoma (46 of 81, 57%). In addition, giant cell tumor of bone displayed a high PSMA labelling in 67% of the cases. In contrast, high PSMA expression was seen in only 0-40% of the non-neoplastic vessels in vascular tumors, while 8% of them expressed PSMA in the tumor cells. Thus, with variable frequency among the different subtypes, a subset of bone and soft tissue tumors, both malignant and intermediate behavior, express PSMA and these patients may benefit from PSMA-targeting PET/CT scans or PSMA targeted radioligand therapy.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30109 - Pathology
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2025
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Virchows Archiv
ISSN
0945-6317
e-ISSN
1432-2307
Volume of the periodical
487
Issue of the periodical within the volume
6
Country of publishing house
DE - GERMANY
Number of pages
11
Pages from-to
1299-1309
UT code for WoS article
001461756500001
EID of the result in the Scopus database
2-s2.0-105002167718